Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead Sciences | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Gilead Sciences

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences

2Q Revenues: $1 billion (+53%)

2Q Earnings: $407.9 million (+54%)

YTD Revenues: $2.1 billion (+51%)

YTD Earnings: $815.3 million (+54%)

Comments: Growth in the quarter was driven by HIV product sales, up 60% to $762.2 million. Atripla, launched in July 2006 in the U.S., achieved $212.4 million in sales. Truvada sales were $385.4 million, up 29%. Also contributing to growth in the quarter were Hepsera sales, up 32% to $75.2 million, and AmBisome sales, up 16% to $64.8 million. Royalty, contract and other revenues from collaborations were $143 million, up 51% in the quarter. R&D expenses in the quarter were $135.9 million, up 50%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters